Latest Price Indications: Capmatinib vs. Savotinib

Capmatinib (Capmatinib) and Savolitinib (Savolitinib) both belong to the tyrosine kinase inhibitor (TKI) class of drugs, especially for the treatment of specific patient groups in non-small cell lung cancer (NSCLC). Both drugs use MET kinase as their main target and have significant efficacy in NSCLC patients with MET exon 14 skipping mutations. They inhibit the proliferation and migration of cancer cells by inhibiting the activity of MET kinase.

Currently, the original drug of capmatinib has not yet been launched in the domestic market. In Hong Kong, the original drug capmatinib with a specification of 200 mg and 60 tablets is priced at around RMB 30,000 per box. The specific price will be adjusted based on exchange rate fluctuations. In overseas markets, for example, the price of the same drug sold in Europe, with 120 tablets per box and 200mg per tablet, may rise to more than 50,000 yuan, also affected by the exchange rate. However, overseas markets also provide more affordable generic drug options. For example, a drug produced in Laos with a specification of 200mg and 56 tablets costs only more than 3,000 yuan. Although the price changes with the exchange rate, the price is significantly lower than that of the original drug.

Unlike capmatinib, saivotinib is already on the market in China and is included in Class B medical insurance, but is only reimbursed for eligible patients. Specifically, it is suitable for adult patients with locally advanced or metastatic NSCLC with MET exon 14 skipping whose disease has progressed after platinum-containing chemotherapy or who are intolerant to standard platinum-containing chemotherapy. In China, the common drug specification is 200mg*21 tablets, and the price per box is about more than 6,000 yuan. After being reimbursed by medical insurance, the actual costs borne by the patient will be reduced. It is worth noting that saivotinib is currently not sold in overseas markets.